Baidu
map

Int Arch Allergy Immunol:成年人过敏性鼻炎中,白藜芦醇初级临床效果评估

2018-03-24 AlexYang MedSci原创

白藜芦醇是一种天然的、非黄酮类多酚物质,具有抗炎症活性。之前有报道指出,白藜芦醇与羧甲基-β-葡聚糖一起使用能够在儿童过敏性鼻炎(AR)中减少鼻部症状。最近,有研究人员调查了白藜芦醇在患有AR的成年人中的治疗效果。研究人员进行了一个安慰剂对照、双盲研究。研究包括了151名(年龄18-60岁)患有重度永久性AR的成年人,并将他们分成安慰剂处理组(n=50)和布地奈德处理组(n=50)以及一个白藜芦醇

白藜芦醇是一种天然的、非黄酮类多酚物质,具有抗炎症活性。之前有报道指出,白藜芦醇与羧甲基-β-葡聚糖一起使用能够在儿童过敏性鼻炎(AR)中减少鼻部症状。最近,有研究人员调查了白藜芦醇在患有AR的成年人中的治疗效果。

研究人员进行了一个安慰剂对照、双盲研究。研究包括了151名(年龄18-60岁)患有重度永久性AR的成年人,并将他们分成安慰剂处理组(n=50)和布地奈德处理组(n=50)以及一个白藜芦醇处理组(n=51)。研究发现,与安慰剂处理组相比,使用白藜芦醇或者布地奈德处理的成年人鼻部症状显著减少。白藜芦醇治疗能够显著的减少血液中IgE,、IL-4、 TNF-α和嗜酸性细胞的水平。另外,白藜芦醇治疗还具有提高患有AR成年人生活质量的作用。

最后,研究人员指出,他们的初始结果表明了鼻内使用白藜芦醇能够显著的改善患有过敏性鼻炎成年人的鼻部症状。

原始出处:

Lv C, Zhang Y, Shen L et al. Preliminary Clinical Effect Evaluation of Resveratrol in Adults with Allergic Rhinitis. Int Arch Allergy Immunol l. 14 Mar 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
    2018-03-26 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
    2018-03-25 为你把脉

    滚滚滚还好还好哈哈哈

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2046947, encodeId=a31d204694e74, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Jul 13 05:47:00 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890926, encodeId=faf81890926b7, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Apr 16 17:47:00 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329092, encodeId=9cf21329092e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484484, encodeId=4d31148448404, content=<a href='/topic/show?id=889e2284233' target=_blank style='color:#2F92EE;'>#临床效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22842, encryptionId=889e2284233, topicName=临床效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fab7968641, createdName=12498d2fm53(暂无昵称), createdTime=Mon Mar 26 10:47:00 CST 2018, time=2018-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299535, encodeId=fd7e29953501, content=滚滚滚还好还好哈哈哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sun Mar 25 12:33:53 CST 2018, time=2018-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=299312, encodeId=67f7299312f0, content=v哈哈哈还好还好哈, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b0171930782, createdName=为你把脉, createdTime=Sat Mar 24 20:13:27 CST 2018, time=2018-03-24, status=1, ipAttribution=)]
    2018-03-24 为你把脉

    v哈哈哈还好还好哈

    0

相关资讯

Ann Allergy Asthma Immunol:过敏性鼻炎病人的嗜碱性粒细胞表现出了胸腺基质淋巴生成素受体的过敏原特异性上调

过敏性鼻炎(AR)的诊断主要基于典型的鼻症状和过敏原敏化测试。然而,有时候在区分AR和非AR患者时具有难度,并且鉴定AR患者的起因性过敏原从而进行针对性的免疫治疗尤其困难。最近,有研究人员鉴定了AR病人之间的差异,使得受试者具有无症状的敏化作用(AS)和受试者没有过敏(NS)能够进行AR的诊断。研究发现,细胞因子受体因子2和它的产物-胸腺基质淋巴生成素受体(TSLPR)在过敏原刺激后的AR患者中的

Int Forum Allergy Rhinol:在过敏性鼻炎中,鼻通气功能是评估鼻一氧化氮诊断价值的重要因素

鼻一氧化氮(NO)在过敏性鼻炎(AR)诊断中的作用是具有争议的。最近,有研究人员在AR病人中,鉴定了能够影响鼻NO水平的因素,并且评估了鼻NO在AR诊断中的作用。研究包括了75名AR病人和31名健康对照。研究发现,鼻阻塞得分、嗜酸细胞阳离子蛋白(ECP)和鼻气道阻力(NAR)与鼻NO独立相关。鼻NO在鼻阻塞得分小于7(轻度到中度阻塞)的患者中的水平与对照相比,具有显著的增加(282.1 ± 122

J Allergy Clin Immunol:Dupilumab在永久过敏性鼻炎和并发哮喘中的效果和安全性评估

Dupilumab是一种抗IL-4Rα单克隆抗体,能够抑制IL-4/IL-13信号,是类型2/Th2免疫疾病的关键驱使因子(比如特应性/过敏性疾病)。在一个关键的阶段2b研究(NCT01854047)中,dupilumab能够减少重度疾病发作,改善肺功能和生活质量,虽然使用了中等剂量到高等剂量的吸入皮质激素和长效β2激动剂,但在不受控制的持续性哮喘病人中仍具有普遍良好的耐受性。最近,有研究人员探究

J Laryngol Otol:永久性过敏性鼻炎儿童标准化特异性舌下免疫治疗长期效果分析

最近,有研究人员观察和分析了永久过敏性鼻炎儿童中,单敏和多敏儿童对屋尘螨过敏的标准化特异性舌下免疫治疗5年时间的治疗效果。研究时间为2007年到2009年,包括了236名永久过敏性鼻炎的儿童,并且被分为2组:组1利用屋尘螨提取物进行了标准化的特异性舌下免疫治疗;另1个小组利用鼻用糖皮质激素和口腔抗组胺药物进行了药物治疗。研究总共包括了193名病人(106在免疫治疗小组和87名在药物治疗小组)完成了

Ther Clin Risk Manag:城市过敏性鼻炎儿童的变化的气源性致敏原谱回顾性研究

最近,有研究人员调查了过去10年的中国广州患有过敏性鼻炎(AR)儿童中,气源性过敏原谱和趋势的变化情况。研究是一个回顾性的研究,包括了4111名鼻高反应的儿童。研究人员对他们进行了血清特异性免疫球蛋白E测量,并在3328名患者中检测到了阳性结果,即为AR。另外,研究人员还对不同气源性致敏的阳性率和趋势进行了评估。研究发现,在AR儿童中,常见的气源性过敏原屋尘螨(HDMs)、猫狗皮屑、蟑螂、霉菌混合

Allergy:过敏性鼻炎患者舌下免疫治疗后,Th2细胞特异性减少

尽管Th2细胞在过敏性疾病,如过敏性鼻炎(AR)中具有很重要的角色,但是能够诱导和维持AR发病机理的因素仍旧不清楚。最近的舌下免疫治疗(SLIT)的发展有希望能够对AR的发病机理进行阐释。然而,哪一类Th2细胞亚群在屋尘螨诱导的AR(HDM-AR)中具有重要作用,SLIT对Th2细胞病理学影响以及Th2细胞亚群与SLIT效果之间的联系还没有明确的解释。最近,有研究人员在89名HDM-AR病人(43

Baidu
map
Baidu
map
Baidu
map